Develops targeted radiopharmaceuticals using proprietary technologies to improve cancer imaging and therapy.
Buy
Sign up to view historical trading trends and place an offer.
Sell
Understand share pricing, list anonymously, and benefit from transparent fees.
Overview
Ratio Therapeutics develops best-in-class targeted radiopharmaceuticals for the treatment of cancer, utilizing innovative technologies such as their proprietary Trillium™ targeting scaffold and PK Modulation platform. The company focuses on creating small molecule agents that combine imaging and therapeutic radioisotopes to accelerate and de-risk the development of cancer therapies.
Buy
Sign up to view historical trading trends and place an offer.
Sell
Understand share pricing, list anonymously, and benefit from transparent fees.
Ratio Therapeutics Management Team
Investors
Bristol Myers Squibb
Catalio Capital Management, LP
Charles and Lynn Schusterman Family Foundation
Cornell Center for Technology Licensing
Duquesne Family Office
Eli Lilly & Company
PAGS Group
Wasatch Venture Fund
Ratio Therapeutics Valuations & Financials
View real-time NPM data on Ratio Therapeutics stock including daily Ratio Therapeutics stock price estimates, valuation history, and historical share price information. Access Ratio Therapeutics financing rounds, secondary trade levels, cap table data, and private company comparable transactions. Use NPM's private company valuation database to track Ratio Therapeutics pricing across six independent market signals. Looking for private company due diligence data sources on Ratio Therapeutics? Get in touch to learn more.
Similar Companies
like Ratio Therapeutics
Podium
Enterprise Software
Customer messaging platform enabling companies to connect at critical touch points.
Farther
FinTech
Combines personalized advisory services with advanced technology to deliver tailored financial solutions.
Dog is Human
Provides at-home testing kits and telehealth integration to streamline remote clinical monitoring.
Huddl.ai
Enterprise Software
AI-powered meeting platform that automates content management, making remote meetings more efficient with searchable, secure documentation.
Mailprotector
Delivers zero trust email security solutions for MSPs with AI-driven threat protection, encryption, and secure file transfer.
BrainHQ
Healthcare & Life Sciences
Empowers individuals to enhance memory, attention and thinking skills through adaptive cognitive exercises.
Tranquis Therapeutics
Develops small molecule drugs to restore immune cell function for treating neurodegenerative and aging-related diseases.
Sight Machine
Industrials
Enables streaming plant data into actionable insights for production improvement, root-cause detection and operational agility.
eQcell
Produces specialized stem cell therapies and regenerative treatments that target debilitating orthopedic conditions in animals.
FAQ
We have answers
Ratio Therapeutics stock does not trade on public stock exchanges. Ratio Therapeutics stock is considered a private security and you need to be an accredited investor to trade shares. To invest in Ratio Therapeutics stock you can either buy shares directly through the company or work with a secondary trading marketplace like Nasdaq Private Market.
Learn more about the secondary market for private company shares on the investors page.
Ratio Therapeutics Stock does not trade on public stock exchanges. In order to sell Ratio Therapeutics shares you need to work directly with the company or with a secondary trading marketplace like Nasdaq Private Market. NPM has more than a decade of experience helping sell shares on the private market to our network of institutional investors.
Learn more about NPM services for selling privately held stock on the Employee Shareholders page.
Read more about how to sell private company stock on the private secondary market:
Ratio Therapeutics does not have a publicly available stock price because it is privately held and not traded on public stock exchanges. Through the NPM Data and Intelligence database from Nasdaq Private Market, you can view Ratio Therapeutics share price and other valuable private market data.
Read more about secondary market private company stock prices:
There is no ticker symbol for Ratio Therapeutics stock because it is a private company. Private companies do not have ticker symbols like public companies, they are identified primarily by using the company ‘street’ name or legal name.
Nasdaq Private Market currently works with employees, ex-employees, and other company investors. In order to sell Ratio Therapeutics stock you need to receive the company’s approval, which Nasdaq Private Market manages on your behalf.
Learn more about selling privately held stock on the Employee Shareholders page.
Read more about how to sell shares of a private company and eligibility for selling privately held stock:
Currently, Nasdaq Private Market only works with accredited entities and institutional investors to purchase private company stock. In order to invest in Ratio Therapeutics stock, you need to be an accredited entity or institutional investor.
Learn more about the Nasdaq Private Market tool kit for investors on the Investor Trading page.
Once you buy or sell, stock share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patent-pending Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.
To learn more about private company stock Transfer and Settlement, check out the Transfer and Settlement page.
Ratio Therapeutics is a private company and has not had an IPO. There is currently no Ratio Therapeutics IPO price. Get started to begin exploring the Nasdaq Private Market Data and Intelligence database and gain access to actionable data related to Ratio Therapeutics IPO.
Learn more about Data and Intelligence private company stock data for institutional investors on the on the NPM Data and Intelligence Product Page.
